A stark financial reality now defines the gene therapy landscape: treatment costs reaching $2 million per patient represent a watershed moment for healthcare economics. This unprecedented price point—far exceeding traditional oncology treatments at $50,000 and annual specialty drugs at $150,000—has created an acute financing crisis within healthcare systems globally.
Health economist William Padula’s analysis reveals that this cost explosion is not merely a pricing problem but a fundamental infrastructure deficit. Payment systems designed for distributed, recurring costs cannot accommodate massive single-intervention investments, even when those interventions provide permanent cures.
The financial barrier threatens to create a two-tiered access system where gene therapies remain available only to wealthy nations and well-insured populations. Healthcare stakeholders must urgently develop scalable financing models capable of managing these extraordinary costs while maintaining treatment accessibility.
Read the full article on GMJ Newsroom.
Was this article helpful?
